US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,320.53

-3.0977-0.23%

Number of Gainers:- -

Number of Losers:3

Number of Flat:- -

PE:- -

High:1,332.36

Open:1,324.16

Low:1,311.24

Close:1,323.63

Loading ...

BRIEF-Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement

Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. -- Barrons.com

NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat

This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working. -- Barrons.com

Press Release: Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

BRIEF-Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025

BRIEF-Gilead Sciences Announces Q1 Estimated Acquired IPR&D

Gilead: for Q1, Expects $253.4M in Acquired Ipr&D Expenses

THOMSON REUTERS

Update: Market Chatter: Novartis Plans to Spend $23 Billion to Build, Expand 10 US Facilities

MT Newswires Live

Novartis Plans $23B Expansion in U.S.

Novartis announces planned $23B investment over five years in U.S.

Novartis Plans to Spend $23 Billion to Build, Expand 10 US Facilities, Reuters Reports

MT Newswires Live

PatientView Ranks Gilead "Best" at ESG

ACCESS Newswire

Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy

MT Newswires Live

Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk

Morgan Stanley Remains a Buy on Gilead Sciences (GILD)

BUZZ-US drugmakers fall as Trump threatens tariffs again

Gilead Sciences Down 3%, Amgen Down 2.9%, Pfizer Down 2.7%

THOMSON REUTERS

Drugmakers Down Premarket After Trump Threatens Tariffs on Sector

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4578/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1320.5336,"timestamp":1745265599999,"preClose":1323.6312,"halted":0,"volume":7938360,"delay":0,"changeRate":-0.00234,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-3.097656,"latestTime":"04-21 16:00:00 EDT","open":1324.1553,"high":1332.3552,"low":1311.2408,"amount":823153740.040305,"amplitude":0.015952,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.378866,"peRate":27.973188,"turnoverRate":0.002595,"increases":0,"decrements":3,"flats":0,"marketCap":348425927064,"floatMarketCap":329406211420},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1332.3552,"amplitude":0.015952,"preClose":1323.6312,"low":1311.2408,"pbRate":"5.378866","latestPrice":1320.5336,"volume":7938360,"delay":0,"open":1324.1553,"prevYearClose":1164.883,"prevWeekClose":1323.6312,"prevMonthClose":1364.0579,"prevQuarterClose":1364.0579,"fiveDayClose":1294.8855,"twentyDayClose":1344.9163,"sixtyDayClose":1188.045,"secType":"PLATE","market":"US","turnoverRate":0.002595,"peRate":27.973188,"marketCap":348425927064,"floatMarketCap":329406211420,"timestamp":1745265599999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":0,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527216205","title":"BRIEF-Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement","url":"https://stock-news.laohu8.com/highlight/detail?id=2527216205","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527216205?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:25","pubTimestamp":1744806321,"startTime":"0","endTime":"0","summary":"BRIEF-Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive EngagementApril 16 (Reuters) - bluebird bio Inc BLUE.O:BLUEBIRD BIO CONFIRM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA9ZCZVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","BLUE","BK4556","BK4139"],"gpt_icon":0},{"id":"2527008415","title":"Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke","url":"https://stock-news.laohu8.com/highlight/detail?id=2527008415","media":"TipRanks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527008415?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:08","pubTimestamp":1744718921,"startTime":"0","endTime":"0","summary":"European drugmaker Novartis , best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.Novartis’ latest move is a reactive and proactive response to an evolving supply chain that increasingly favors manufacturing in host countries. Novartis’ recent financial performance, which allows such investments, and its prescient adaptations make me bullish on its stock.As has been the case for the last few quarters, Novartis’ revenue growth was driven","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/novartis-nvs-unleashes-23bn-strategic-120841357.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-nvs-unleashes-23bn-strategic-120841357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BK4W5M84.HKD","LLY","LU0256863811.USD","LU1868836914.USD","LU1989771016.USD","LU1914381329.SGD","LU2491049909.HKD","IE00BFTCPJ56.SGD","LU1032466523.USD","IE00BJJMRZ35.SGD","LU0203345920.USD","LU1057294990.SGD","LU1720051108.HKD","LU2750360641.GBP","LU1720051017.SGD","LU2360106947.USD","LU0640476718.USD","LU1868837136.USD","BK4550","LU0689472784.USD","LU0203201768.USD","LU0354030511.USD","JNJ","LU2237438978.USD","SG9999015986.USD","LU2471134879.HKD","LU1059921491.USD","LU0097036916.USD","LU0471298777.SGD","LU1551013342.USD","LU1623119135.USD","BK4559","NVS","LU0094547139.USD","IE00BLSP4239.USD","IE00BJLML261.HKD","IE00B2B36J28.USD","LU1267930813.SGD","LU0792757196.USD","LU0456855351.SGD","IE0009355771.USD","SGXZ51526630.SGD","IE00BSNM7G36.USD","LU1506573853.SGD","LU2265009873.SGD","LU0417517546.SGD","LU2430703178.SGD","LU0234572021.USD","LU2264538146.SGD","BK4578"],"gpt_icon":1},{"id":"2527116967","title":"This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2527116967","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527116967?lang=en_us&edition=fundamental","pubTime":"2025-04-15 01:27","pubTimestamp":1744651620,"startTime":"0","endTime":"0","summary":"A single infusion of a Verve Therapeutics gene-editing treatment cut dangerously high levels of cholesterol in a group of patients by more than half. The company reported Monday that cholesterol levels fell by 59% in the first month, with no significant side effects, for patients getting the high dose.There were 14 patients in Verve's Phase 1 trail, which it called Heart-2. Higher doses of its genetic medicine led to deeper cuts in the harmful form of cholesterol known as LDL-C.\"These initial Heart-2 data are promising with respect to both safety and efficacy and suggest the potential for a new era of cardiovascular disease treatment where a single dose might lead to lifelong control of LDL-C,\" said Harvard Medical School professor Eugene Braunwald, in Verve's press release.As with many firms developing therapies, Verve is testing its PCSK9 editor on the sickest patients fi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013342.USD","LU1804176565.USD","LU1623119135.USD","IE00B1BXHZ80.USD","VERV","LU2112291526.USD","IE0009355771.USD","IE0002141913.USD","IE00B2B36J28.USD","AMGN","LU1917777945.USD","LU1814569148.SGD","BK4539","LU1069344957.HKD","SGXZ81514606.USD","LU0640476718.USD","SG9999014880.SGD","LU0203202063.USD","LU1291159041.SGD","LU2106854487.HKD","LU0354030511.USD","IE00BK4W5L77.USD","BK4578","LU0320765992.SGD","LU1064131342.USD","LU2361045086.USD","LU2237443895.HKD","LU1868836757.USD","LU0094547139.USD","LU0820561818.USD","BK4532","LU0238689110.USD","LU2264538146.SGD","LU0417517546.SGD","REGN","LU1983299246.USD","SG9999015978.USD","NVS","LU1366192091.USD","LU1988902786.USD","SG9999015945.SGD","LU2089984988.USD","LU2237443622.USD","SG9999001176.SGD","LU0385154629.USD","LU1023059063.AUD","SG9999014906.USD","LU0006306889.USD","LU2357305700.SGD"],"gpt_icon":1},{"id":"2526761082","title":"NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2526761082","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526761082?lang=en_us&edition=fundamental","pubTime":"2025-04-12 01:17","pubTimestamp":1744391820,"startTime":"0","endTime":"0","summary":"Swiss pharma giant Novartis NVS announced a planned $23 billion investment over five years in U.S.-based infrastructure.Backed by this investment, the company intends to manufacture all key drugs for its U.S. patients in the country.NVS' decision to expand its current manufacturing, research and technology presence across the country follows President Trump's announcement of tariffs on pharmaceutical imports.The company's shares are up in pre-market. Novartis’ shares have risen 8.7% year to date against the industry’s decline of 8.2%.NVS expanded its manufacturing and R&D presence in the country by investing in 10 facilities, including seven brand-new ones.Over the next five years, Novartis will establish a biomedical research innovation hub in San Diego, CA, its second global R&D hub in the United States. This is expected to open during 2028-2029.These investments will ensure Novartis has manufacturing capacity in the United States for all its core technology platforms, including smal","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvs-plans-invest-23b-us-171700008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0208291251.USD","LU0211331839.USD","IE0009355771.USD","BK4532","BAYRY","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BJJMRZ35.SGD","NVS","LU0320765489.SGD","BK4588","ADMA","IE00BFTCPJ56.SGD","BK4578","BK4139","BK4007","LU0070302665.USD"],"gpt_icon":0},{"id":"2526666102","title":"This Pharma Giant Will Invest $23 Billion in the U.S. It's a Sign Trump's Tariffs Are Working. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2526666102","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526666102?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:28","pubTimestamp":1744374480,"startTime":"0","endTime":"0","summary":"At least one European pharmaceutical giant seems to have gotten President Donald Trump's message about bringing manufacturing to the U.S.: The maker of top-selling drugs like heart medicine Entresto and Cosentyx for psoriasis, Novartis, just announced it will spend $23 billion to expand its U.S.-based production.With the new manufacturing capacity, 100% of its key medicines for U.S. patients will be made in the U.S., Novartis said late Thursday.The company is one of Europe's biggest drugmakers alongside Novo Nordisk, Sanofi, Roche Holding AG, and AstraZeneca. With a market capitalization of almost $200 billion and 2024 sales of over $50 billion, Novartis' pharma footprint is already large.The Swiss company will now invest billions to pump up production and research & development in the U.S. over the next five years. It will expand current manufacturing as well as creating seven new facilities, creating thousands of American jobs, it said.Increased R&D includes a new research hub in San","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE0009355771.USD","BK4585","IE0002141913.USD","IE00B2B36J28.USD","BK4568","LU0154236417.USD","LU0889565916.HKD","LU2456880835.USD","BK4588","LU0211331839.USD","IE00BKVL7J92.USD","AZN","LU2417539215.USD","BK4578","LU0320765992.SGD","BK4007","IE00BFXG1179.USD","BK4532","LU0070302665.USD","LU1829250122.USD","IE00B4R5TH58.HKD","LU2462157665.USD","IE00BJJMRZ35.SGD","LU2236285917.USD","BK4599","IE00BZ1G4Q59.USD","NVS","LU0109394709.USD","IE00BJT1NW94.SGD","LU1093756168.USD","LU1093756325.SGD","LU0320765489.SGD","SNY","LU0208291251.USD"],"gpt_icon":1},{"id":"2526440955","title":"Press Release: Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526440955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526440955?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:56","pubTimestamp":1744318560,"startTime":"0","endTime":"0","summary":"Gilead Sciences, Inc.  announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2025 financial results and provide a business update.A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.For more information on Gilead Sciences, please visit the company's website at www.gilead.c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","BK4532","IE00BKVL7J92.USD","LU1839511570.USD","LU1430594728.SGD","BK4585","LU1585245621.USD","LU0109394709.USD","LU2089984988.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","BK4139","BK4588","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU2087621335.USD","BK4550","BK4578","IE0002270589.USD","LU0320765992.SGD","LU1066053197.SGD","BK4566","LU1571399168.USD","LU0234570918.USD","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","BK4583","GILD","LU0889565916.HKD","IE00B3T34201.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2526054464","title":"BRIEF-Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526054464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526054464?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:49","pubTimestamp":1744318188,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025Gilead Sciences Inc GILD.O:GILEAD SCIENCES TO RELEASE FIRST QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, APRIL 24, 2025Source text: ID:nBw9tkyLqaFurther company coverage: GILD.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA1Q8XW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4583","BK4532","LU2089984988.USD","IE00BKVL7J92.USD","LU1430594728.SGD","BK4585","LU1839511570.USD","LU2468319806.SGD","BK4139","LU1066051498.USD","IE00B19Z3B42.SGD","LU0058720904.USD","IE0002270589.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","BK4568","LU0320765992.SGD","IE00B19Z3581.USD","BK4578","LU1066053197.SGD","LU0889565916.HKD","LU1571399168.USD","LU0234570918.USD","LU0289739699.SGD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","GILD","IE00B3T34201.USD","LU0109394709.USD","LU2087621335.USD","BK4588","BK4550"],"gpt_icon":0},{"id":"2526544327","title":"BRIEF-Gilead Sciences Announces Q1 Estimated Acquired IPR&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2526544327","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526544327?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:47","pubTimestamp":1744318024,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead Sciences Announces Q1 Estimated Acquired IPR&DApril 10  - Gilead Sciences Inc GILD.O:GILEAD: FOR Q1, EXPECTS $253.4M IN ACQUIRED IPR&D EXPENSESGILEAD:  FOR Q1 , EXPECTS CHARGE OF ABOUT $0.16 TO BOTH GAAP AND NON-GAAP EPS, IN ACQUIRED IPR&D EXPENSESSource text: [ID:]Further company coverage: GILD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO15B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4139","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","LU1839511570.USD","LU1585245621.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4588","IE00B19Z3581.USD","LU0058720904.USD","IE00B7SZLL34.SGD","BK4550","IE00B3T34201.USD","BK4585","BK4566","LU0889565916.HKD","BK4532","BK4578","GILD","BK4583","LU1066051498.USD","LU0109394709.USD","LU1066053197.SGD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU2087621335.USD","LU1571399168.USD","LU2468319806.SGD","IE00BKVL7J92.USD","LU0320765992.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"2526754931","title":"Gilead: for Q1, Expects $253.4M in Acquired Ipr&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2526754931","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526754931?lang=en_us&edition=fundamental","pubTime":"2025-04-11 04:12","pubTimestamp":1744315969,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO15B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE00BKVL7J92.USD","LU1066053197.SGD","LU1066051498.USD","BK4568","BK4566","IE00B3T34201.USD","IE00BSNM7G36.USD","LU2089984988.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","BK4583","LU1839511570.USD","IE0002270589.USD","BK4532","BK4578","IE00B19Z3B42.SGD","LU1430594728.SGD","BK4588","IE00B7SZLL34.SGD","GILD","BK4585","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","LU2087621335.USD","LU1571399168.USD","LU0058720904.USD","LU0289739699.SGD","LU0320765992.SGD","LU1585245621.USD","BK4550","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2526543123","title":"Update: Market Chatter: Novartis Plans to Spend $23 Billion to Build, Expand 10 US Facilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2526543123","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526543123?lang=en_us&edition=fundamental","pubTime":"2025-04-11 03:13","pubTimestamp":1744312412,"startTime":"0","endTime":"0","summary":"Novartis  plans to invest $23 billion in building and expanding 10 facilities in the US over the next five years in response to possible drug import tariffs under the Trump administration, Reuters reported Thursday, citing the company.The company plans to construct six new manufacturing plants, including factories for raw pharmaceutical ingredients, and a new research and development site in San Diego, California, according to the report.The projects, set for completion over the next five years, are expected to create over 1,000 specialized jobs and an additional 3,000 support and construction jobs, according to Reuters.The company has reportedly not decided on exact locations for the new manufacturing sites.Novartis did not immediately respond to a request for comment from MT Newswires.Price: 103.71, Change: -0.14, Percent Change: -0.14","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","BGSX","BK4578","BK4588","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE00BJJMRZ35.SGD","BK4007","IE0009355771.USD","IE0002141913.USD","BK4585","IE00B4R5TH58.HKD","LU0208291251.USD","LU0070302665.USD","NVS","LU0211331839.USD","BK4532"],"gpt_icon":0},{"id":"2526472510","title":"Novartis Plans $23B Expansion in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2526472510","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526472510?lang=en_us&edition=fundamental","pubTime":"2025-04-11 02:29","pubTimestamp":1744309740,"startTime":"0","endTime":"0","summary":"Pharmaceutical company Novartis said it plans to expand U.S.-based manufacturing and research and development, with a total investment of $23 billion over the next five years.The company said it is planning to increase its R&D activity with a new $1.1 billion research hub in the San Diego area, its second in the U.S. The new complex is expected to open between 2028 and 2029.Novartis also intends to build four new manufacturing facilities, including 3 which will make biologics drug substances, drug products, device assembly and packaging. The other facility will make chemical drug substances, oral solids dosage forms and packaging. The new manufacturing capacity will enable Novartis to produce 100% of its key medicines end-to-end in the U.S., according to the company.The company also plans to construct a pair of radioligand therapy manufacturing facilities in Florida and Texas, and expand three RLT manufacturing facilities in Indianapolis, Millburn, NJ, and Carlsbad, CA.The investments ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","IE00BJT1NW94.SGD","IE0002141913.USD","BK4532","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0070302665.USD","LU0211331839.USD","BK4588","IE00B2B36J28.USD","LU0320765489.SGD","NVS","IE00B4R5TH58.HKD","IE0009355771.USD","BK4007","IE00BJJMRZ35.SGD","BK4585"],"gpt_icon":0},{"id":"2526517079","title":"Novartis announces planned $23B investment over five years in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2526517079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526517079?lang=en_us&edition=fundamental","pubTime":"2025-04-11 02:10","pubTimestamp":1744308612,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced a planned $23B investment over five years in U.S.-based infrastructure, ensuring all key Novartis medicines for U.S. patie...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-planned-23b-investment-over-five-years-in-u-s?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-planned-23b-investment-over-five-years-in-u-s?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE00BFTCPJ56.SGD","LU0070302665.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0208291251.USD","NVS","IE00B4R5TH58.HKD","IE0009355771.USD","BK4532","IE00B2B36J28.USD","LU0320765489.SGD","BK4588","BK4585","LU0211331839.USD","BK4578","IE0002141913.USD"],"gpt_icon":0},{"id":"2526124085","title":"Novartis Plans to Spend $23 Billion to Build, Expand 10 US Facilities, Reuters Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2526124085","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526124085?lang=en_us&edition=fundamental","pubTime":"2025-04-11 01:48","pubTimestamp":1744307301,"startTime":"0","endTime":"0","summary":"Price: 102.23, Change: -1.63, Percent Change: -1.56","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002141913.USD","IE00B4R5TH58.HKD","BGSX","LU0070302665.USD","BK4532","BK4588","IE0009355771.USD","IE00BJT1NW94.SGD","LU0208291251.USD","IE00BFTCPJ56.SGD","BK4585","NVS","LU0320765489.SGD","BK4578","IE00B2B36J28.USD","BK4007","IE00BJJMRZ35.SGD","LU0211331839.USD"],"gpt_icon":0},{"id":"2526033595","title":"PatientView Ranks Gilead \"Best\" at ESG","url":"https://stock-news.laohu8.com/highlight/detail?id=2526033595","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526033595?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:50","pubTimestamp":1744289400,"startTime":"0","endTime":"0","summary":"NORTHAMPTON, MA / ACCESS Newswire / April 10, 2025 / At Gilead, putting people first is central to all we do. That's why we're proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries. In a new report from UK-based PatientView, we were ranked \"best\" at ESG by patient groups who work with us.About Gilead SciencesGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/patientview-ranks-gilead-best-esg-125000748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1430594728.SGD","GILD","BK4550","IE0002270589.USD","LU0320765992.SGD","IE00B7SZLL34.SGD","BK4578","LU0889565916.HKD","LU0109394709.USD","ESG","BK4568","BK4532","LU1839511570.USD","BK4566","BK4585","IE00B19Z3B42.SGD","LU2089984988.USD","LU0058720904.USD","IE00BZ1G4Q59.USD","LU2087621335.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU0289739699.SGD","LU2468319806.SGD","LU0234570918.USD","BK4588","IE00BSNM7G36.USD","BK4139","LU1585245621.USD","IE00B3T34201.USD","LU1066051498.USD","BK4583","IE00BKVL7J92.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"2526955292","title":"Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy","url":"https://stock-news.laohu8.com/highlight/detail?id=2526955292","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526955292?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:18","pubTimestamp":1744283886,"startTime":"0","endTime":"0","summary":"Ideaya Biosciences (IDYA) said Thursday it launched a phase 1/2 expansion in a clinical trial of its experimental IDE397 treatment in combination with Gilead Sciences' (GILD) Trodelvy in methylthioade","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4583","LU0320765992.SGD","IE00B19Z3581.USD","BK4588","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU0109394709.USD","BK4139","BK4578","BK4566","IE0002270589.USD","IE00B19Z3B42.SGD","BK4550","LU0234570918.USD","LU2087621335.USD","IE00BZ1G4Q59.USD","LU1066051498.USD","LU1571399168.USD","LU0058720904.USD","IE00BSNM7G36.USD","IDYA","BK4585","LU1839511570.USD","BK4532","LU0289739699.SGD","LU0889565916.HKD","GILD","IE00B3T34201.USD","LU2089984988.USD","LU2468319806.SGD","LU1585245621.USD","BK4568","LU1430594728.SGD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2526899425","title":"Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526899425","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526899425?lang=en_us&edition=fundamental","pubTime":"2025-04-10 15:36","pubTimestamp":1744270560,"startTime":"0","endTime":"0","summary":"0736 GMT - European pharma stocks jump at Thursday's market open, mirroring broader market gains, after U.S. President Trump announced a 90-day pause on so-called reciprocal tariffs. The Stoxx 600 health index surges around 7.2%, outpacing the wider Stoxx 600's 1.2% rise. While pharmaceuticals have so far been spared, Trump reiterated on Tuesday that tariffs on imported medicines remain a possibility. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","RHHBY","03165","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","GSK.UK","BK4532","BAYRY","LU0208291251.USD","BK4585","GSK","LU0889565916.HKD","IE00B4R5TH58.HKD","LU2236285917.USD","LU0320765489.SGD","IE00BFXG1179.USD","LU2456880835.USD","IE0002141913.USD","NVS","LU0211331839.USD","LU2462157665.USD","IE00B2B36J28.USD","BK4007","LU2417539215.USD","BK4588","LU0320765992.SGD","IE0009355771.USD","LU1829250122.USD","BK4568","SNY","AZN","BK4578"],"gpt_icon":0},{"id":"2526834365","title":"Morgan Stanley Remains a Buy on Gilead Sciences (GILD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526834365","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526834365?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:17","pubTimestamp":1744201067,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-gilead-sciences-gild?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","LU0320765992.SGD","LU1720051108.HKD","BK4504","IE00B19Z3581.USD","LU0158827781.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","LU0225283273.USD","BK4534","LU1668664300.SGD","LU0106831901.USD","LU1989772840.SGD","BK4578","LU0314104364.USD","BK4566","LU1548497426.USD","BK4581","IE0002270589.USD","LU1363072403.SGD","BK4550","LU0158827948.USD","LU0234570918.USD","IE00BZ1G4Q59.USD","LU1571399168.USD","LU0058720904.USD","IE00BSNM7G36.USD","LU1839511570.USD","BK4585","LU2347655156.SGD","LU1720051017.SGD","BK4127","BK4532","LU0289739699.SGD","LU0795875086.SGD","LU0098860793.USD","GILD","IE00B3T34201.USD","LU1074936037.SGD","LU2468319806.SGD","BK4568","LU0320765646.SGD","LU2111349929.HKD","LU1430594728.SGD","LU1732800096.USD","LU1989772923.USD","LU2089284900.SGD","LU0912757837.SGD","LU0006306889.USD","BK4516"],"gpt_icon":0},{"id":"2526351104","title":"BUZZ-US drugmakers fall as Trump threatens tariffs again","url":"https://stock-news.laohu8.com/highlight/detail?id=2526351104","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526351104?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:46","pubTimestamp":1744195603,"startTime":"0","endTime":"0","summary":"BUZZ-US drugmakers fall as Trump threatens tariffs again** Shares of some U.S. drugmakers fall premarket after U.S. President Donald Trump reiterated plans for a \"major\" tariff on all pharmaceutical imports as his \"reciprocal\" tariffs took effect** Trump had also threatened the duties on Friday, after his first set of \"reciprocal\" tariffs announced last week exempted pharma products** Shares of Gilead Sciences GILD.O down 2.6%, Eli Lilly LLY.N down 1.5%, Biogen BIIB.O down 1.1% and Pfizer PFE.N down 2.8%** Amgen AMGN.O shares fall 2.3%, Merck MRK.N down 2%, AbbVie ABBV.N down 2.5%** The U.S. president has said that the tariffs will incentivize drug companies to move their operations to the U.S.** Brokerage BMO Capital Markets says the tariffs on pharmaceuticals will \"likely do little to shift manufacturing back to the US\" as the country already has robust biomanufacturing and fill-and-finish onshore ** Up to last close, LLY down 5.9%, MRK down 20.6%, BIIB down 25.4%, AMGN up 7.5% and G","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nL3N3QN14Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203201768.USD","SG9999003800.SGD","IE00B7SZLL34.SGD","LU0310800379.SGD","LU0106261372.USD","IE00B19Z3B42.SGD","AMGN","LU2237443465.HKD","LU1003077747.HKD","SGXZ81514606.USD","LU0795875169.SGD","BK4578","GILD","LU0354030511.USD","LU1585245621.USD","SG9999014914.USD","BIIB","LU1037948541.HKD","LU0949170772.SGD","LU2237443978.SGD","IE00B4R5TH58.HKD","SG9999018857.SGD","LU0689472784.USD","LU1720051108.HKD","MRK","IE00BVYPNV92.GBP","LU0354030438.USD","LU0208291251.USD","LU1061106388.HKD","LU0211328371.USD","LU0471298694.HKD","LU2237443895.HKD","LU1496350502.SGD","LU0861579265.USD","LU1989772840.SGD","SG9999015952.SGD","BK4566","LU1116320737.USD","LU0795875086.SGD","LU0385154629.USD","LU2242652126.USD","BK4581","LU0070302665.USD","LU0203345920.USD","LU0708995401.HKD","LU1868836591.USD","ABBV","LU0889565916.HKD","LU1988902786.USD","LLY"],"gpt_icon":1},{"id":"2526359452","title":"Gilead Sciences Down 3%, Amgen Down 2.9%, Pfizer Down 2.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526359452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526359452?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:34","pubTimestamp":1744194899,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nL3N3QN152:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1061106388.HKD","LU1267930490.SGD","LU0310799852.SGD","LU0203345920.USD","LU1732800096.USD","LU0912757837.SGD","LU0661504455.SGD","SG9999018857.SGD","BIIB","LU0265550946.USD","LU1623119135.USD","LU2468319806.SGD","LU0321505868.SGD","LU1291159041.SGD","LU0965509101.SGD","LU0795875086.SGD","LU0320765646.SGD","LU1883839398.USD","IE0004445239.USD","LU2552382132.HKD","MRK","LU0708995401.HKD","IE00B19Z3B42.SGD","LU1929549753.HKD","LU0289739699.SGD","BK4578","IE00B7SZLL34.SGD","LU0689472784.USD","LU0097036916.USD","LU1718418525.SGD","LU1244550577.SGD","GILD","LU0985320562.USD","IE00BSNM7G36.USD","SG9999013999.USD","SGXZ31699556.SGD","LU1551013342.USD","PFE","IE00BJJMRZ35.SGD","AMGN","LU1066053197.SGD","LU2491050154.USD","IE00B2B36J28.USD","LU0385154629.USD","ABBV","LLY","LU1732799900.SGD","LU0211328371.USD","LU0640476718.USD","BK4516"],"gpt_icon":0},{"id":"2526359437","title":"Drugmakers Down Premarket After Trump Threatens Tariffs on Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2526359437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526359437?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:34","pubTimestamp":1744194898,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nL3N3QN152:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0640476718.USD","AMGN","LU0265550946.USD","BK4578","LU0708995401.HKD","LU0965509101.SGD","LU0912757837.SGD","LU1551013342.USD","LU1061106388.HKD","LU0795875086.SGD","IE00B2B36J28.USD","LU0321505868.SGD","LU1623119135.USD","LU1267930490.SGD","LU2491050154.USD","BIIB","LU1883839398.USD","IE00B19Z3B42.SGD","LU2552382132.HKD","ABBV","BK4516","IE00B7SZLL34.SGD","LU2468319806.SGD","PFE","LU0985320562.USD","LU0211328371.USD","LU1929549753.HKD","LU1732800096.USD","MRK","LU0097036916.USD","LU0385154629.USD","LU0310799852.SGD","IE00BJJMRZ35.SGD","LU1244550577.SGD","LU0689472784.USD","LU1291159041.SGD","SG9999013999.USD","IE00BSNM7G36.USD","LU0661504455.SGD","LU1066053197.SGD","SGXZ31699556.SGD","LU0289739699.SGD","GILD","LU0320765646.SGD","LU1718418525.SGD","SG9999018857.SGD","LLY","LU0203345920.USD","LU1732799900.SGD","IE0004445239.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}]}}